Effect of N-Acetylcysteine for Prevention of Contrast Nephropathy in Patients with Moderate to Severe Renal Insufficiency: A Randomized Trial

American Journal of Kidney Diseases

Volumn 43, Issue 5, 2004, Pages 801-808

  Fung, Jeffrey W H ^a   Szeto, C C ^b   Chan, Wilson W M ^b   Kum, Leo C C ^b   Chan, Anna K Y ^b   Wong, John T H ^b   Wu, Eugene B ^b   Yip, Gabriel W K ^b   Chan, Joseph Y S ^b   Yu, Cheuk M ^b   Woo, Kam S ^b   Sanderson, John E ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NONE

Author keywords

Contrast nephropathy (CN); N Acetylcysteine (NAC)

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; STATINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 11144356595     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.01.010     Document Type: Article

References (48)

1. Barrett BJ, Parfrey PS: Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 331:1449-1450, 1994
2. Chertow GM, Christiansen CL, Cleary DP: Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med 155:1505-1511, 1995
3. Gruberg L, Mehran R, Dangas G, et al: Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 52:409-416, 2001
4. McCullough PA, Wolyn R, Rocher LL, et al: Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 103:368-375, 1997
5. Murphy SW, Barrett BJ, Parfrey PS: Contrast nephropathy. J Am Soc Nephrol 11:177-182, 2000
6. Erley CM, Duda SH, Schlepckow S, et al: Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 45:1425-1431, 1994
7. Kapoor A, Sinha N, Sharma RK, et al: Use of dopamine in prevention of contrast induced acute renal failure: A randomized study. Int J Cardiol 53:233-236, 1996
8. Kurnik BR, Allgren RL, Genter FC, et al: Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 31:674-680, 1998
9. Hans SS, Hans BA, Dhillon R, et al: Effect of dopamine on renal function after arteriography in patients with preexisting renal insufficiency. Am Surg 64:432-436, 1998
10. McCullough PA, Manley HJ: Prediction and prevention of contrast nephropathy. J Interv Cardiol 14:547-558, 2001
11. Solomon R, Werner C, Mann D, et al: Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331:1416-1420, 1994
12. Brezis M, Rosen S: Hypoxia of the renal medulla - Its implications for disease. N Engl J Med 332:647-655, 1995
13. Porter G: Contrast associated nephropathy: Presentation, pathophysiology and management. Miner Electrolyte Metab 20:232-243, 1994
14. Bakris GL, Lass N, Gaber AO, et al: Radiocontrast medium-induced declines in renal function: A role for oxygen radicals. Am J Physiol 258:F115-F120, 1990
15. Zager RA, Johnson AC, Hanson SY: Radiographic contrast media-induced tubular injury: Evaluation of oxidant stress and plasma membrane integrity. Kidney Int 64:128-139, 2003
16. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180-184, 2000
17. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 89:356-358, 2002
18. Shyu KG, Cheng JJ, Kuan P: Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 40:1383-1388, 2002
19. Briguori C, Manganelli F, Scarpato P, et al: Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40:298-303, 2002
20. Allaqaband S, Tumuluri R, Malik AM, et al: Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 57:279-283, 2002
21. Durham JD, Caputo C, Dokko J, et al: A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 62:2202-2207, 2002
22. Vallero A, Cesano G, Pozzato M, et al: Contrast nephropathy in cardiac procedures: No advantages with prophylactic use of N-acetylcysteine (NAC). G Ital Nefrol 19:529-533, 2002
23. Kay J, Chow WH, Chan TM, et al: Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial. JAMA 289:553-558, 2003
24. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ: A rapid protocol for the prevention of contrast-induced renal dysfunction: The RAPPID study. J Am Coll Cardiol 41:2114-2118, 2003
25. Boccalandro F, Amhad M, Smalling RW, Sdringola S: Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 58:336-341, 2003
26. Goldenberg I, Jonas M, Matetzki S, et al: Contrast-associated nephropathy and clinical outcome of patients with chronic renal insufficiency undergoing cardiac catheterization: Lack of additive benefit of acetylcysteine to saline hydration. J Am Coll Cardiol 41:S537A, 2003 (suppl B; abstr)
27. Loutrianakis E, Stella D, Hussain A, et al: Randomized comparison of fenoldopam and N-acetylcysteine to saline in the prevention of radiocontrast nephropathy. J Am Coll Cardiol 41:S327A, 2003 (suppl A; abstr)
28. Oldemeyer JB, Cichowski EK, Wurdeman RL, Packard KA, Biddle WP, Mooss AN: Prophylactic acetylcysteine is not effective in preventing contrast-induced nephropathy following coronary angiography. J Am Coll Cardiol 41: S84A, 2003 (suppl A; abstr)
29. Le Feuve C, Mahmoud EI, Beygui F, et al: The role of acetylcysteine on prevention of renal function worsening after coronary angiography. Eur Heart J 24:2657A, 2003 (abstr)
30. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C: Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet 362:598-603, 2003
31. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130:461-470, 1999
32. Sonntag O, Scholer A: Drug interference in clinical chemistry: Recommendation of drugs and their concentrations to be used in drug interference. Ann Clin Biochem 38:376-385, 2001
33. Weisberg LS, Kurnik PB, Kurnik BR: Radiocontrast-induced nephropathy in humans: Role of renal vasoconstriction. Kidney Int 41:1408-1415, 1992
34. Agmon Y, Peleg H, Greenfeld Z, et al: Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 94:1069-1075, 1994
35. Murakami R, Machida M, Tajima H, et al: Plasma endothelin, nitric oxide and atrial natriuretic peptide levels in humans after abdominal angiography. Acta Radiol 43:340-343, 2002
36. Sheridan AM, Bonventre JV: Pathophysiology of ischemic acute renal failure. Contrib Nephrol 132:7-21, 2001
37. Bakris GL, Gaber AO, Jones JD: Oxygen free radical involvement in urinary Tamm Horsfall protein excretion after intrarenal injection of contrast medium. Radiology 175:57-60, 1990
38. Hizoh I, Haller C: Radiocontrast-induced renal tubular cell apoptosis. Hypertonic versus oxidative stress. Invest Radiol 37:428-434, 2002
39. Arstall MA, Yang J, Stafford I, Betts WH, Horowitz JD: N-Acetylcysteine in combination with nitroglycerin and streptokinase for treatment of evolving acute myocardial infarction: Safety and biochemical effects. Circulation 92:2855-2862, 1995
40. Safirstein R, Andrade L, Vieira JM: Acetylcysteine and nephrotoxic effects of radiocontrast agents - A new use for an old drug. N Engl J Med 343:210-212, 2000
41. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein RL: N-Acetylcysteine ameliorates ischemic renal failure. Am J Physiol 272:F292-F298, 1997
42. Lepor NE, Matur VS: Radiocontrast nephropathy. Curr Interv Cardiol Rep 2:335-341, 2000
43. Hou SH, Bushindky DA, Wish JB, et al: Hospital acquired renal insufficiency: A prospective study. Am J Med 74:243-248, 1983
44. Schwab SJ, Hlatky MA, Pieper KS, et al: Contrast nephrotoxicity: A randomized controlled trial of a nonionic and ionic radiographic contrast agent. N Engl J Med 320:149-153, 1989
45. Steingberg EP, Moore RD, Powe NR, et al: Safety and cost effectiveness of high-osmolality as compared with low-osmolality iodinated contrast material in patients undergoing cardiac angiography. N Engl J Med 326:425-430, 1992
46. Aspelin P, Aubry P, Fransson SG, et al: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348:491-499, 2003
47. Amersey R, Baig MK, Bhundoo S, et al: N-Acetylcysteine and contrast-induced nephropathy after invasive cardiac procedures in patients with abnormal renal function, a meta-analysis. Eur Heart J 24:2658A, 2003 (abstr)
48. Stevens MA, McCullough PA, Tobin KJ, et al: A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: Results of the PRINCE Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 33:403-411, 1999